Ilias Läber
Director/Board Member chez HOLCIM LTD
Fortune : 725 303 $ au 31/03/2024
Profil
Ilias Läber is currently serving as the Chairman at Quercis Pharma AG.
He is also a Director at Swiss Automotive Group AG, Holcim Ltd., and CANCOM SE.
In addition, he holds the position of Member-Supervisory Board at Grand Resort Bad Ragaz AG.
Previously, Dr. Läber worked as a Non-Executive Director at Panalpina Welttransport (Holding) AG from 2013 to 2019.
He also served as the Managing Director & Partner at Cevian Capital AG from 2008 to 2019.
Prior to that, he worked as an Associate Principal at Mckinsey & Co. (Switzerland) from 2001 to 2008.
Dr. Läber obtained his graduate and doctorate degrees from the University of Zurich.
He also holds a graduate degree from the Swiss Federal Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HOLCIM LTD
0,00% | 31/12/2022 | 8 000 ( 0,00% ) | 725 303 $ | 31/03/2024 |
Postes actifs de Ilias Läber
| Sociétés | Poste | Début |
|---|---|---|
| HOLCIM LTD | Director/Board Member | 04/05/2022 |
| CANCOM SE | Director/Board Member | - |
Swiss Automotive Group AG
 Swiss Automotive Group AG Wholesale DistributorsDistribution Services Swiss Automotive Group AG engages in the manufacture and distribution of car and commercial vehicle spare parts. The firm also sells repair parts, lubricants, chemicals, accessories, workshop equipment, and consumables. It also provides maintenance and repair services. The company was founded in 2009 and is headquartered in Cham, Switzerland. | Director/Board Member | - |
Quercis Pharma AG
 Quercis Pharma AG Internet Software/ServicesTechnology Services Quercis Pharma AG is a private biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is focused on developing a pipeline of late-stage clinical studies that aim to prevent venous thromboembolism (VTE) in cancer patients. The Swiss company's lead drug candidate acts as an antithrombotic with significantly lower risk of adverse events than existing treatments. Quercis Pharma also targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola, and COVID-19. The company is preparing to conduct a number of studies for the treatment of SCD (phase 2) and COVID-19 (phase 2/3). Quercis plans to initiate two phase 3 studies for the prevention of VTE in pancreatic cancer and glioblastoma patients and will pursue FDA approval for the prevention of VTE in all cancer types based on these studies. The company was founded in 2019 by Thomas Lines, who has been the CEO since then. | Chairman | 01/01/2019 |
Grand Resort Bad Ragaz AG
 Grand Resort Bad Ragaz AG Hotels/Resorts/Cruise linesConsumer Services Grand Resort Bad Ragaz AG engages in the operation of luxury hotels. It operates through the following segments: Resort, Tamina Therme, Casino and Clinic Bad Ragaz. The company was founded in 1242 and is headquartered in Bad Ragaz, Switzerland. | Director/Board Member | 01/05/2021 |
Anciens postes connus de Ilias Läber
| Sociétés | Poste | Fin |
|---|---|---|
Cevian Capital AG
 Cevian Capital AG Investment ManagersFinance Cevian Capital AG (Cevian) is an independent alternative investment management firm headquartered in Pfäffikon, Switzerland. The firm was founded by Lars Förberg and Christer Gardell in 2007. Cevian manages assets of pension funds, endowments, foundations and sovereign wealth funds. | Portfolio Manager-Equities | 01/01/2019 |
| PANALPINA WELTTRANSPORT (HOLDING) AG | Director/Board Member | 01/01/2019 |
Mckinsey & Co. (Switzerland)
 Mckinsey & Co. (Switzerland) Miscellaneous Commercial ServicesCommercial Services Mckinsey & Co. (Switzerland) provides business management consulting services. The private company is based in Geneva, Switzerland. | Corporate Officer/Principal | 01/01/2008 |
Formation de Ilias Läber
| University of Zurich | Doctorate Degree |
| Swiss Federal Institute of Technology | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CANCOM SE | Technology Services |
 | Consumer Services |
| HOLCIM LTD | Non-Energy Minerals |
| Entreprise privées | 5 |
|---|---|
Panalpina Welttransport (Holding) AG
 Panalpina Welttransport (Holding) AG AirlinesTransportation Panalpina Welttransport (Holding) AG engages in the provision of freight transportation and logistics services. It offers air freight, ocean freight, energy solutions, supply chain solutions, road and rail services, security, business implementation, and online tools. It operates through the following geographical segments: Asia Pacific; Europe; Middle East, Africa, and CIS; and Americas. The company was founded in 1954 and is headquartered in Basel, Switzerland. | Transportation |
Swiss Automotive Group AG
Swiss Automotive Group AG Wholesale DistributorsDistribution Services Swiss Automotive Group AG engages in the manufacture and distribution of car and commercial vehicle spare parts. The firm also sells repair parts, lubricants, chemicals, accessories, workshop equipment, and consumables. It also provides maintenance and repair services. The company was founded in 2009 and is headquartered in Cham, Switzerland. | Distribution Services |
Cevian Capital AG
Cevian Capital AG Investment ManagersFinance Cevian Capital AG (Cevian) is an independent alternative investment management firm headquartered in Pfäffikon, Switzerland. The firm was founded by Lars Förberg and Christer Gardell in 2007. Cevian manages assets of pension funds, endowments, foundations and sovereign wealth funds. | Finance |
Mckinsey & Co. (Switzerland)
Mckinsey & Co. (Switzerland) Miscellaneous Commercial ServicesCommercial Services Mckinsey & Co. (Switzerland) provides business management consulting services. The private company is based in Geneva, Switzerland. | Commercial Services |
Quercis Pharma AG
Quercis Pharma AG Internet Software/ServicesTechnology Services Quercis Pharma AG is a private biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is focused on developing a pipeline of late-stage clinical studies that aim to prevent venous thromboembolism (VTE) in cancer patients. The Swiss company's lead drug candidate acts as an antithrombotic with significantly lower risk of adverse events than existing treatments. Quercis Pharma also targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola, and COVID-19. The company is preparing to conduct a number of studies for the treatment of SCD (phase 2) and COVID-19 (phase 2/3). Quercis plans to initiate two phase 3 studies for the prevention of VTE in pancreatic cancer and glioblastoma patients and will pursue FDA approval for the prevention of VTE in all cancer types based on these studies. The company was founded in 2019 by Thomas Lines, who has been the CEO since then. | Technology Services |
